1. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference
- Author
-
Jaishri O. Blakeley, Cynthia Hawkins, Fausto J. Rodriguez, Stefan M. Pfister, Uri Tabori, Brian R. Rood, Antonio Iavarone, Roger J. Packer, Eric Bouffet, Tobey J. MacDonald, Stephen Albert Johnston, David T.W. Jones, Lindsay Kilburn, David H. Gutmann, Michael Fisher, Eugene Hwang, Yuan Zhu, Vijay Ramaswamy, and Jason Fangusaro
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Neurofibromatosis 1 ,Pilocytic Astrocytomas ,Reviews ,pilocytic astrocytomas ,neurofibromatosis type 1 ,Older patients ,Internal medicine ,Glioma ,medicine ,AcademicSubjects/MED00300 ,Animals ,Humans ,Neurofibromatosis ,Child ,neoplasms ,business.industry ,Brain Neoplasms ,Consensus conference ,molecular-targeted therapy ,medicine.disease ,eye diseases ,nervous system diseases ,gliomas ,Editor's Choice ,Disease Models, Animal ,AcademicSubjects/MED00310 ,Neurology (clinical) ,immunotherapy ,business - Abstract
Gliomas are the most common primary central nervous system tumors occurring in children and adults with neurofibromatosis type 1 (NF1). Over the past decade, discoveries of the molecular basis of low-grade gliomas (LGGs) have led to new approaches for diagnosis and treatments. However, these new understandings have not been fully applied to the management of NF1-associated gliomas. A consensus panel consisting of experts in NF1 and gliomas was convened to review the current molecular knowledge of NF1-associated low-grade “transformed” and high-grade gliomas; insights gained from mouse models of NF1-LGGs; challenges in diagnosing and treating older patients with NF1-associated gliomas; and advances in molecularly targeted treatment and potential immunologic treatment of these tumors. Next steps are recommended to advance the management and outcomes for NF1-associated gliomas.
- Published
- 2020